JP2024526878A5 - - Google Patents
Info
- Publication number
- JP2024526878A5 JP2024526878A5 JP2024503529A JP2024503529A JP2024526878A5 JP 2024526878 A5 JP2024526878 A5 JP 2024526878A5 JP 2024503529 A JP2024503529 A JP 2024503529A JP 2024503529 A JP2024503529 A JP 2024503529A JP 2024526878 A5 JP2024526878 A5 JP 2024526878A5
- Authority
- JP
- Japan
- Prior art keywords
- retrovirus
- polynucleotide
- cancer
- activator
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224330P | 2021-07-21 | 2021-07-21 | |
| US63/224,330 | 2021-07-21 | ||
| PCT/US2022/074024 WO2023004396A1 (en) | 2021-07-21 | 2022-07-21 | Regulated viral delivery systems and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526878A JP2024526878A (ja) | 2024-07-19 |
| JP2024526878A5 true JP2024526878A5 (enExample) | 2025-07-28 |
Family
ID=84980508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503529A Pending JP2024526878A (ja) | 2021-07-21 | 2022-07-21 | 調節されたウイルス送達システムおよびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240327866A1 (enExample) |
| EP (1) | EP4373952A4 (enExample) |
| JP (1) | JP2024526878A (enExample) |
| WO (1) | WO2023004396A1 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1059356B1 (en) * | 1999-06-09 | 2005-11-02 | Universite Pierre Et Marie Curie Paris Vi | Replicating retroviral constructs, preparation and uses for gene delivery |
| AU2001265187A1 (en) * | 2000-05-30 | 2001-12-11 | Baylor College Of Medicine | Chimeric viral vectors for gene therapy |
| CN111479921B (zh) * | 2017-09-18 | 2024-08-02 | 埃克苏马生物技术公司 | 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物 |
-
2022
- 2022-07-21 JP JP2024503529A patent/JP2024526878A/ja active Pending
- 2022-07-21 US US18/579,829 patent/US20240327866A1/en active Pending
- 2022-07-21 WO PCT/US2022/074024 patent/WO2023004396A1/en not_active Ceased
- 2022-07-21 EP EP22846841.9A patent/EP4373952A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240182924A1 (en) | Genomic insulator elements and uses thereof | |
| JP5265643B2 (ja) | 免疫治療組成物調製用のレンチウイルスベクター | |
| Renaud-Gabardos et al. | Internal ribosome entry site-based vectors for combined gene therapy | |
| CN105705645B (zh) | 逆转录病毒载体 | |
| Reichenbach et al. | A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor | |
| EP2909324B1 (en) | Retroviral vector with mini-promoter cassette | |
| JP7672114B2 (ja) | 安定したレンチウイルスパッケージング細胞株およびその作成方法 | |
| Diaz et al. | A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy | |
| CN1234075A (zh) | 慢病毒载体 | |
| JP2012503986A5 (enExample) | ||
| JP2016526920A5 (enExample) | ||
| CA2346931A1 (en) | Gene delivery system and methods of use | |
| CN105579581A (zh) | 具有优化的a凸出物的重组载体 | |
| US20240401077A1 (en) | Koala retrovirus envelope gylcoproteins and uses thereof | |
| KR20020013486A (ko) | 전사 조절부위로서 이종 유전자의 프로모터와 원래 유전자시작 코돈의 상부에 위치한 모든 5' 비해독 부위를 갖는고효율 동물세포 발현벡터 | |
| Hofacre et al. | Efficient therapeutic protein expression using retroviral replicating vector with 2A peptide in cancer models | |
| JP2024503703A5 (enExample) | ||
| EP1045922B1 (en) | Reconstituting retroviral vector (recon vector) for targeted gene expression | |
| EP1478750B1 (en) | Gene expression by positive feedback activation of a cell type-specific promoter | |
| JPH11502706A (ja) | シュードタイプレトロウイルス粒子 | |
| JP2001502904A (ja) | レトロウイルスベクター | |
| CN117866107A (zh) | 靶向cd5分子的嵌合抗原受体t细胞及其抗肿瘤应用 | |
| WO2018101498A1 (ko) | 유전자치료 벡터시스템 및 전구약물 유전자 | |
| EP1059356B1 (en) | Replicating retroviral constructs, preparation and uses for gene delivery | |
| Roth et al. | MGMT enrichment and second gene co-expression in hematopoietic progenitor cells using separate or dual-gene lentiviral vectors |